Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
All-trans retinoic acid for severe fever with thrombocytopenia syndrome (SFTS)
ChiCTR2300076238Phase 2Recruiting
- Sponsor
- Beijing Institute of Microbiology and Epidemiology
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of tretinoin in severe fever with thrombocytopenia syndrome (SFTS) (2 arms), sponsored by Beijing Institute of Microbiology and Epidemiology. Primary endpoint: 28-day case fatality rate of SFTS. Started Jun 2023; status: recruiting.
02
Drugs
tretinoin
03
Conditions
severe fever with thrombocytopenia syndrome (SFTS)
Beyond the preview
Go deeper on ChiCTR2300076238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076238.